Article

PDF
Access to the PDF text
Advertising


Free Article !

Archives of cardiovascular diseases
Volume 112, n° 3
pages 187-198 (mars 2019)
Doi : 10.1016/j.acvd.2018.10.002
Received : 22 August 2018 ;  accepted : 2 October 2018
Cliical research

Disparities in death rates in women with peripartum cardiomyopathy between advanced and developing countries: A systematic review and meta-analysis
Disparité dans le taux de décès chez les femmes ayant une cardiomyopathie du péripartum selon la survenue dans un pays émergent ou développé : revue systématique et méta-analyse
 

Kate Kerpen a, Paraskevi Koutrolou-Sotiropoulou b, Chencan Zhu c, Jie Yang d, Jennifer-A. Lyon e, Fabio V. Lima f, Kathleen Stergiopoulos a,
a Division of Cardiovascular Medicine, Department of Medicine, Stony Brook University Medical Center, State University of New York, Stony Brook, Nichols road, 11794 NY, United States of America 
b Division of Cardiovascular Medicine, Mayo Clinic, 55905 Rochester, MN, USA 
c Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, 11794 NY, USA 
d Department of Family, Population and Preventive Medicine, Stony Brook University Medical Center, Stony Brook, 11794 NY,USA 
e Library Services, Children's Mercy Kansas City, 64108 Kansas City, MO, USA 
f Department of Medicine, Brown University, Rhode Island Hospital, 02903 Providence, RI, USA 

Corresponding author.
Summary

There is limited information about differences in maternal deaths from peripartum cardiomyopathy (PPCM) between advanced and developing countries. To review the literature to define the global prevalence of death from PPCM, and to determine the differences in PPCM mortality rates and risk factors between advanced and developing countries. Studies in the English language reporting mortality data on patients with PPCM were included from searches of MEDLINE, Embase, CINAHL, the Cochrane Library, the Web of Science Core Collection and Scopus from 01 January 2000 to 11 May 2016. Of the 4294 articles identified, 1.07% were included. The primary outcome was death; rates of heart transplant, acute myocardial infarction, heart failure, arrhythmia, cerebrovascular events, embolism and cardiac arrest were recorded. Studies were categorized as having been conducted in advanced or developing countries. Data from 46 studies, 4925 patients and 13 countries were included. There were 22 studies from advanced countries (n =3417) and 24 from developing countries (n =1508); mean follow-up was 2.6 (range 0–8.6) years. Overall mortality prevalence was 9% (95% confidence interval [CI] 6–11%). The mortality rate in developing countries (14%, 95% CI 10–18%) was significantly higher than that in advanced countries (4%, 95% CI 2–7%). There was no difference in the prevalence of risk factors (chronic hypertension, African descent, multiple gestation and multiparity) between advanced and developing countries. Studies with a higher prevalence of women of African descent had higher death rates (correlation coefficient 0.29, 95% CI 0.13–0.52). The risk of death in women with PPCM was higher in developing countries than in advanced countries. Women of African descent had an increased risk of death.

The full text of this article is available in PDF format.
Résumé

Les données concernant les différences sur le taux de mortalité maternelle de cardiomyopathie du péripartum restent limitées pour ce qui concerne la différence entre les pays développés ou émergents. Revue de la littérature pour définir une prévalence globale du taux de décès lié à une cardiomyopathie du péripartum et déterminer les différences pour ce qui concerne les facteurs de risque entre les pays développés ou émergents. Étude de la littérature anglaise rapportant les taux de mortalité chez les patientes porteuses d’une cardiomyopathie du péripartum à partir d’une recherche sur les bases de données MEDLINE, Embase, CINAHL, Cochrane, Collection Web of Science Core et Scopus entre le 1er janvier 2000 et le 11 mai 2016. Parmi les 4294 articles identifiés, 1.07 % ont été finalement inclus. Le critère de jugement principal était le décès, le taux de transplantation cardiaque, d’infarctus du myocarde, d’insuffisance cardiaque, d’arythmie cardiaque, d’évènements cérébraux vasculaires, d’embolie et d’arrêt cardiaque avec collection systématique de ces informations. Les études ont été caractérisées comme ayant été ou non effectuées dans un pays développé ou émergent. Les données de 46, soit 4 925 patients dans 13 pays ont été inclues, ont été colligées 22 études provenant des pays développés (n =3417) et 24 études provenant des pays émergents (n =1508). La durée moyenne de suivi était de 2,6 ans (0–8.6). La prévalence de la mortalité globale était de 9 % (IC 95 % 6–11 %). Le taux de mortalité dans les pays émergents était de 14 % (IC 95 % 10–18 %), significativement plus élevé que celui observé dans les pays développés (taux de mortalité 4 %, IC 95 % 2–7 %). Il n’y avait pas de différence pour ce qui concerne la prévalence des facteurs de risque (HTA chronique, origine africaine, grossesses multiples, multiparité) entre les pays émergents et développés. Les études avec une prévalence plus élevée de femmes d’origine africaine rapportaient un taux plus élevé de décès avec un coefficient de corrélation à 0,29, IC 95 % 0,13–0,52. Le risque de décès chez les femmes porteuses d’une cardiomyopathie du péripartum est plus élevé dans les pays émergents comparativement aux pays développés. Les femmes d’origine africaine ont un risque accru de décès.

The full text of this article is available in PDF format.

Keywords : Peripartum cardiomyopathy, Outcomes, Advanced countries, Developing countries, Meta-analysis

Mots clés : Cardiomyopathie du péripartum, Suivi, Évènement cardiovasculaire, Pays développés, Pays émergents, Méta-nalyse

Abbreviations : CMR, ESC, PPCM


Background

Peripartum cardiomyopathy (PPCM) is an idiopathic cardiomyopathy, defined as the development of cardiac failure in the last month of pregnancy or within 5 months of delivery, with an ejection fraction of<45%, in the absence of an alternative aetiology or previous heart disease [1, 2]. PPCM is a global disease, with an estimated prevalence of about 1 in 1000 pregnancies, with a possible trend towards an increase in prevalence in certain regions of the world, including the USA [3, 4, 5]. The reported mortality from PPCM varies widely from<1% to>30%, depending on patient population studied, type of study, follow-up time, definition of PPCM and availability and access to adequate treatment and resources [5, 6]. There is limited information regarding possible differences in maternal death rates among women with PPCM in advanced countries compared with developing countries. While previous studies have pointed to factors associated with the development of PPCM, such as age>30 years, black race, pre-eclampsia, hypertension and multiple gestations [7], it is unknown whether there are differences in the prevalences of these risk factors between developing and advanced countries, and if there is any impact on death rates. Additionally, previous studies have pointed to worse outcomes in women of African descent [8], but it is not clear if African descent is a risk factor for death in PPCM.

In this study, we sought to review the contemporary global PPCM literature in order to define the global prevalence of death, to compare the prevalence of death in advanced and developing countries, and to define the prevalence of risk factors for the development of PPCM in advanced and developing countries, and their impact on death rates.

Methods
Literature search

The methods and inclusion criteria were specified in advance and documented in a protocol. We followed the MOOSE (Meta-analysis of Observational Studies in Epidemiology) guidelines [9]. Six bibliographic databases were used: MEDLINE (PubMed; National Library of Medicine, NIH, Bethesda, MD, USA); Embase (Elsevier, Amsterdam, Netherlands); CINAHL (EBSCOhost; EBSCO Information Services, Ipswich, MA, USA); the Cochrane Library (John Wiley & Sons, Hoboken, NJ, USA); the Web of Science Core Collection (Clarivate Analytics, Philadelphia, PA, USA); and Scopus (Elsevier). Searches were limited to English language articles published between 01 January 2000 and 11 May 2016, regardless of geographical origin. If the publication type was a case report, letter, commentary or editorial, the article was excluded. The following PubMed (MEDLINE) search strategy was used, and then adapted appropriately for the other databases: “(((cardiomyopathies[mh] OR cardiomyopath*[tw]) AND (Pregnancy[mh] OR pregnan*[tw] OR gestation[tw] OR peripartum[tw])) OR “peripartum cardiomyopathy”[tw] OR “peripartum-associated cardiomyopathy”[tw] OR “peripartum-associated cardiomyopathy”[tw]) AND English[la] AND 2000:2016[dp] NOT (Case Reports[pt] OR “case study”[tw] OR “case report”[tw] OR “case reports”[tw] OR “case studies”[tw] OR “case series”[tw] OR letter[pt] OR comment[pt] OR editorial[pt] OR news[pt])”. Bibliographic database searching was supplemented by citation tracking (checking selected article cited reference lists) and consulting with experts in the field.

Study selection

Once the literature search was completed, articles were imported into EndNote software (Clarivate Analytics) and duplicate citations were removed. The article set was then imported into Covidence (www.covidence.org;/ Covidence, Melbourne, Australia), an online organizational tool for systematic reviews. The titles and abstracts of the studies were independently screened by two authors (K.K. and F. V. L.; Figure 1), and exclusions were based on the following predefined criteria:

not written in the English language;
not a primary research article (e.g. a case report or a review) or;
did not mention PPCM in the title or abstract.



Figure 1


Figure 1. 

Flow diagram depicting the process of study selection for inclusion in the systematic review and meta-analysis, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for reporting systematic reviews and meta-analyses. PPCM: peripartum cardiomyopathy.

Zoom

Once both authors agreed upon each inclusion/exclusion decision, both authors then independently assessed the full-text articles for eligibility. The following predefined exclusion criteria were applied:

death was not reported;
sample size was<20;
data overlap between studies;
no risk factor data reported (i.e. hypertension, African descent, multiparity, multiple gestation);
PPCM sample was a subgroup and not the primary study population and;
PPCM was not the primary diagnosis.

For exclusion criterion (3), if there was data overlap between studies, the study with the largest sample size was included. Once the final set of studies was chosen, data were extracted independently for the predefined categories by two authors (K.K., P. K.-S.), and then cross-checked and corrected.

Data extraction
Definition of diagnosis of PPCM

The definitions and criteria that each study used to establish the diagnosis of PPCM in their patient population were recorded.

Risk factors for PPCM

The rates of different risk factors for PPCM, including age, chronic hypertension, pre-eclampsia/eclampsia, gestational hypertension, African descent, multiparity and multiple gestations, were recorded. Data on hypertension were collected from the studies, and subclassified by type as specified by the author (chronic hypertension, gestational hypertension, pre-eclampsia and eclampsia). All other hypertensive syndromes were classified as “hypertension not otherwise specified”. Heart transplant refers to those listed or those who received a transplant.

Outcome measures

Outcomes of interest recorded were death, heart transplant, acute myocardial infarction, heart failure, arrhythmia, cerebrovascular events, embolism and cardiac arrest.

Country group

Studies were divided into representative subgroups of advanced or developing countries according to the International Monetary Fund classification, as previously described [10, 11, 12]. “USA”, “Germany”, “Japan” and “Israel” were classified as advanced; “Turkey”, “Africa”, “Haiti”, “South Africa”, “Pakistan”, “China”, “Nigeria”, “India” and “Argentina” were classified as developing.

Statistical analysis

Meta-analyses and forest plots were completed for each variable for overall prevalence as well as subgroup prevalence in developing countries and advanced countries. Cochran's Q test was used to test heterogeneity among studies. If the equal variance hypothesis was rejected, a random-effect model was used to estimate the pooled prevalence; otherwise a fixed-effect model was used. Freeman-Tukey (double arcsine) transformation for proportions was used in the estimation [13]. No pooled prevalence of a variable was estimated if there were fewer than five studies reporting that variable's prevalence. Sensitivity analysis was done by estimating the pooled prevalence after excluding one specific study at a time to ensure that no single study was unduly influencing the results. 95% confidence intervals (CIs) based on the Z-test were reported for all estimated prevalence. Permutation tests were used to compare prevalences of pre-eclampsia, hypertension, African descent, multiple gestation and multiparity between advanced and developing countries. Weighted correlation coefficient was used to examine the linear relationship between pre-eclampsia/African descent prevalence and death rate. Here, the weighted correlation coefficient (between variables x and y) was calculated, using the formula:
(∑[weight x][weight y][x−mean x][y−weighted mean y])/√([∑(weight x)2(x−weighted mean x)2][∑(weight y)2(y−weighted y])

where weighted mean:
x=(∑[x][weight x]/(∑[weight x]

and weight is the reciprocal of the CI length for the prevalence within a specific study. 95% bootstrapped CIs were reported for weighted correlation coefficients. Statistical analysis was performed using the R package “metafor” (The R Foundation, Vienna, Austria), and the significance level was set at 0.05.

Results

Overall, data from 46 studies (n =4925, range 20–1337) and 13 countries were included in this analysis (Table 1); there were 22 studies from advanced countries (n =3417) and 24 from developing countries (n =1508). The mean duration of follow-up was 2.6 (range 0–8.6) years. Most studies (70%) used the National Heart, Lung and Blood Institute and Office of Rare Diseases Workshop definition of PPCM, or a modified version of it [1]; however, there were differences in the absolute cut-off for left ventricular ejection fraction. The mean age was 29.7 (range 21–34) years.

The overall pooled prevalence rate of pre-eclampsia/eclampsia was 16% (95% CI 12–21%; Table 2), of gestational hypertension was 21% (95% CI 15–28%), of chronic hypertension was 24% (95% CI 15–34%), of African descent was 48% (95% CI 32–64%), of multiple gestations was 66% (95% CI 56–74%) and of multiparity was 11% (95% CI 8–14%). There were no significant differences in the prevalence of risk factors for PPCM in developing compared with advanced countries, with the exception of hypertension not otherwise specified.

In Table 2, the overall prevalence of death was 9% (95% CI 6–11%; range 0–33%) and of heart transplant was 4% (95% CI 1–7%; range 0–34%). Our analysis revealed that there was a significant difference in the death rate between advanced countries (4%, 95% CI 2–7%) and developing countries (14%, 95% CI 10–18%; Figure 2).



Figure 2


Figure 2. 

Forest plot showing prevalence estimates for death in women with PPCM in developing and advanced countries. The red arrow and dotted line represent the prevalence of death in advanced countries; the blue arrow and dotted line represent the prevalence of death in developing countries.

Zoom

Pre-eclampsia prevalence was not significantly correlated to death rates in this analysis (weighted correlation coefficient 0.15, 95% CI 0.70–0.87). African descent prevalence and death rates were positively correlated (weighted correlation coefficient 0.29, 95% CI 0.13–0.52).

Discussion

To the best of our knowledge, the present study is the largest global contemporary systematic review and meta-analysis performed to date of PPCM studies describing the overall prevalence of death. PPCM is a global disease with similar risk factors in advanced and developing countries. A large proportion of women of African descent (48%) were represented in the present analysis. Death was prevalent in 9% of patients studied, while the risk of death was notably higher in women with PPCM from developing countries compared with advanced countries. While pre-eclampsia was not associated with an increased risk of death in this study population, studies that had a higher percentage of women of African descent tended to report an increased risk of death in this global study population.

A significant difference in death between advanced and developing countries was present, and is not surprising. The overall death rate was 4% in advanced countries and 14% in developing countries. Potential explanations contributing to the poorer outcomes seen in developing countries could include socioeconomic disparities in lack of access to care and education, and access to less optimal medical therapy [14]. Differences in the death rates are not fully explained by differences in the prevalence of risk factors for the development of PPCM in the studies included here. While differences in mortality at 1 month follow-up were not noted in a large registry of patients with PPCM between European Society of Cardiology (ESC) and non-ESC countries, the lack of mortality difference may be related to registry patients from advanced-care hospitals receiving state-of-the-art care, in addition to limited follow-up time [6]. Moreover, non-ESC countries were not necessarily developing countries (i.e. countries from North America, among others). Notably, in a recent single-centre study from within the USA, questions about socioeconomic variables and access to care on disease progression were raised in women with PPCM [8]. In the present study, while we were unable to record socioeconomic variables other than country of origin, we recorded data available on heart transplants; however, several of the studies from developing countries noted that heart transplant was not an available treatment option. This could be a surrogate of availability of advanced treatment options, and may corroborate the concept that treatment modalities in developing compared with advanced countries may differ. Future studies should address the influence of socioeconomic variables on the outcomes in PPCM.

The follow-up time of each individual study is one of the major complicating factors in assessing an accurate death rate in this population. Some authors reported on inpatient mortality alone, while others reported prolonged follow-up periods in the order of years, which may account for the wide variability in the death rate. Recent studies have reported low inpatient mortality rates, which are reassuring [6, 15]; however, these rates may not reflect the true mortality or natural history of this disease. Certainly, there is room for improvement in this area, as the long-term prognosis of this disease has not been defined clearly. Moreover, there are patients that fail to reach medical attention before they are properly diagnosed, because of lack of education, lack of access to care or subtlety of the symptom complex, and unfortunately may experience cardiac events or die. These patients would not be reflected in any of the studies recorded, and may be missed by most analyses. Focusing on early diagnosis, education and treatment may be key elements in having a positive impact on disease severity and survival.

African-American women have significantly higher odds of having PPCM compared with their non-African-American counterparts [16, 17]; they often have worse outcomes and more frequent transplants [16, 17]. In our study, we found that studies that had a higher percentage of women of African descent tended to report an increased risk of death. In the Investigations of Pregnancy-Associated Cardiomyopathy study, a multicentre study of PPCM outcomes in North America, black women had more left ventricular dysfunction initially and at 12-month follow-up [18]. Additionally, in a recent single-centre retrospective cohort study, African-American women with PPCM had a different disease profile to non-African-American women; African-American women were more likely to present later in the postpartum period, and were more likely to present with an ejection fraction<30% and to fail to recover [8].

We estimated prevalence rates for various risk factors in women with PPCM, and found few differences in the major risk factors for PPCM. There was a significant difference for hypertension not otherwise specified, but not for pre-eclampsia or for chronic or gestational hypertension. Surprisingly, studies that had higher rates of pre-eclampsia were not associated with death. Another meta-analysis on PPCM, performed by Bello et al. [19], found an association with a higher prevalence of hypertensive disorders in patients with PPCM than in the general population, supporting the concept of hypertensive disorders in the pathogenesis of PPCM. Our study and that of Bello et al. [19] noted similar overall rates of pre-eclampsia/eclampsia. Interestingly, we were not able to find any statistical differences in most risk factor rates between developing and advanced countries. The classification of hypertensive disorders of pregnancy can be complicated in clinical practice. The reporting of these disorders is not standardized, and may be difficult to discern accurately from retrospective cohort studies. Moreover, hypertensive syndromes of pregnancy exist on a spectrum of less severe to more severe, and can be acute or chronic as well as new or pre-existing, further complicating classification. Notably, in a study of PPCM hospitalizations from the National Inpatient Sample, pre-eclampsia, severe pre-eclampsia, valvular heart disease, multiple gestation and caesarean delivery were independently associated with an increased risk of major adverse cardiac events [15]. Moreover, in a recent single-centre retrospective cohort study, PPCM with concomitant pre-eclampsia was associated with increased morbidity and mortality compared with PPCM not complicated by pre-eclampsia [20].

The vast majority of studies evaluating the degree of cardiac disease in PPCM have focused on left ventricular dysfunction informed by echocardiography [1]. However, the advent and increasing usage of cardiovascular magnetic resonance (CMR) in recent years has led it to become the imaging modality of choice in the diagnosis of cardiomyopathies, especially non-ischaemic heart disease. Moreover, multiparametric CMR allows for better evaluation of right ventricular structure and function than traditional echocardiography, and thus new insights into the phenotypic profile of PPCM can be gained [21]. In the last decade, CMR has started to be applied to evaluate cardiac dysfunction, particularly right ventricular dysfunction, in patients with PPCM [22, 23]; Right ventricular dysfunction and dilatation are observed in about one third of patients with PPCM at time of diagnosis, and portend worse outcomes [21].

PPCM has traditionally been managed with standard medical therapy for heart failure. With new insights into the pathophysiology of PPCM and the damaging role of cleaved prolactin fragments (16kDa N-terminal fragment of prolactin), studies are increasingly recognizing bromocriptine as a potential disease-specific therapy for PPCM. Hilfiker-Kleiner et al. recently demonstrated in a multicentre trial the significant benefit of even a week of therapy with bromocriptine. Furthermore, bromocriptine was well-tolerated in that study, with no patient mortality or need for heart transplant or left ventricular assist device [24].

Study limitations

These data should be interpreted within the context of certain limitations. This is a meta-analysis of the pooled results reported from each individual study because individual patient-level data were not available. As a meta-analysis, this study is intrinsically limited to the strengths and weaknesses of the included studies, as well as the search criteria and the inclusion and exclusion criteria set. The data were extracted mainly from retrospective studies, which can have their own biases and limitations. Patients studied in registries, retrospective analyses or administrative datasets may not be representative of patients seen in actual clinical practice. Data on PPCM from developing countries is probably underestimated in the published literature; therefore, the true prevalence of outcomes and risk factors may be under-represented. In addition, the International Monetary Fund classification may be a gross oversimplification of a country's status, although it is the best available classification.

Conclusions

To date, this study is the largest global contemporary systematic review and meta-analysis of PPCM studies to examine the prevalence of death from and risk factors for PPCM. The risk of death in women with PPCM was higher in developing countries compared with advanced countries. Women with PPCM of African descent had an increased risk of death. Future studies should target early diagnosis and treatment as well as public health measures aimed towards these vulnerable patients.

Funding

None.

Disclosure of interest

The authors declare that they have no competing interest.


Acknowledgments

We acknowledge the statistical support provided by the Biostatistical Consulting Core of Stony Brook University School of Medicine.

References

Pearson G.D., Veille J.C., Rahimtoola S., and al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review JAMA 2000 ;  283 : 1183-1188 [cross-ref]
Sliwa K., Hilfiker-Kleiner D., Petrie M.C., and al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy Eur J Heart Fail 2010 ;  12 : 767-778 [cross-ref]
Mielniczuk L.M., Williams K., Davis D.R., and al. Frequency of peripartum cardiomyopathy Am J Cardiol 2006 ;  97 : 1765-1768 [inter-ref]
Kolte D., Khera S., Aronow W.S., and al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study J Am Heart Assoc 2014 ;  3 : e001056
Lima F.V., Yang J., Xu J., Stergiopoulos K. National Trends and in-hospital outcomes in pregnant women with heart disease in the United States Am J Cardiol 2017 ;  119 : 1694-1700 [inter-ref]
Sliwa K., Mebazaa A., Hilfiker-Kleiner D., and al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM Eur J Heart Fail 2017 ;  9 : 1131-1141 [cross-ref]
Arany Z., Elkayam U. Peripartum cardiomyopathy Circulation 2016 ;  133 : 1397-1409 [cross-ref]
Irizarry O.C., Levine L.D., Lewey J., and al. Comparison of clinical characteristics and outcomes of peripartum cardiomyopathy between African American and Non-African American Women JAMA Cardiol 2017 ;  2 : 1256-1260 [cross-ref]
Stroup D.F., Berlin J.A., Morton S.C., and al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group JAMA 2000 ;  283 : 2008-2012 [cross-ref]
Roos-Hesselink J.W., Ruys T.P., Stein J.I., and al. Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology Eur Heart J 2013 ;  34 : 657-665 [cross-ref]
IMF World economic outlook update  :  (2016). [Available from: weo].
van Hagen I.M., Boersma E., Johnson M.R., and al. Global cardiac risk assessment in the Registry of Pregnancy and Cardiac disease: results of a registry from the European Society of Cardiology Eur J Heart Fail 2016 ;  18 : 523-533 [cross-ref]
Freeman M.F., Tukey J.W. Transformations related to the angular and the square root Ann Math Stat 1950 ;  21 : 607-611 [cross-ref]
Hilfiker-Kleiner D., Sliwa K. Pathophysiology and epidemiology of peripartum cardiomyopathy Nat Rev Cardiol 2014 ;  11 : 364-370 [cross-ref]
Lima F.V., Parikh P.B., Zhu J., Yang J., Stergiopoulos K. Association of cardiomyopathy with adverse cardiac events in pregnant women at the time of delivery JACC Heart Fail 2015 ;  3 : 257-266 [cross-ref]
Gentry M.B., Dias J.K., Luis A., Patel R., Thornton J., Reed G.L. African-American women have a higher risk for developing peripartum cardiomyopathy J Am Coll Cardiol 2010 ;  55 : 654-659 [cross-ref]
Goland S., Modi K., Bitar F., and al. Clinical profile and predictors of complications in peripartum cardiomyopathy J Card Fail 2009 ;  15 : 645-650 [cross-ref]
McNamara D.M., Elkayam U., Alharethi R., and al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy) J Am Coll Cardiol 2015 ;  66 : 905-914 [cross-ref]
Bello N., Rendon I.S., Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis J Am Coll Cardiol 2013 ;  62 : 1715-1723 [cross-ref]
Lindley K.J., Conner S.N., Cahill A.G., Novak E., Mann D.L. Impact of preeclampsia on clinical and functional outcomes in women with peripartum cardiomyopathy Circ Heart Fail 2017 ;  10 : e003797
Haghikia A., Rontgen P., Vogel-Claussen J., and al. Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study Esc Heart Fail 2015 ;  2 : 139-149 [cross-ref]
Barone-Rochette G., Rodiere M., Lantuejoul S. Value of cardiac MRI in peripartum cardiomyopathy Arch Cardiovasc Dis 2011 ;  104 : 263-264 [cross-ref]
Arora N.P., Mohamad T., Mahajan N., and al. Cardiac magnetic resonance imaging in peripartum cardiomyopathy Am J Med Sci 2014 ;  347 : 112-117 [cross-ref]
Hilfiker-Kleiner D., Haghikia A., Berliner D., and al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study Eur Heart J 2017 ;  38 : 2671-2679 [cross-ref]
Afana M., Brinjikji W., Kao D., and al. Characteristics and in-hospital outcomes of peripartum cardiomyopathy diagnosed during delivery in the United States From the Nationwide Inpatient Sample (NIS) database J Card Fail 2016 ;  22 : 512-519 [cross-ref]
Akil M.A., Bilik M.Z., Yildiz A., and al. Peripartum cardiomyopathy in Turkey: experience of three tertiary centres J Obstet Gynaecol 2016 ;  36 : 574-580 [cross-ref]
Amos A.M., Jaber W.A., Russell S.D. Improved outcomes in peripartum cardiomyopathy with contemporary Am Heart J 2006 ;  152 : 509-513 [inter-ref]
Bernstein P.S., Magriples U. Cardiomyopathy in pregnancy: a retrospective study Am J Perinatol 2001 ;  18 : 163-168 [cross-ref]
Biteker M., Ilhan E., Biteker G., Duman D., Bozkurt B. Delayed recovery in peripartum cardiomyopathy: an indication for long-term follow-up and sustained therapy Eur J Heart Fail 2012 ;  14 : 895-901 [cross-ref]
Blauwet L.A., Libhaber E., Forster O., and al. Predictors of outcome in 176 South African patients with peripartum cardiomyopathy Heart 2013 ;  99 : 308-313 [cross-ref]
Brar S.S., Khan S.S., Sandhu G.K., and al. Incidence, mortality, and racial differences in peripartum cardiomyopathy Am J Cardiol 2007 ;  100 : 302-304 [inter-ref]
Chapa J.B., Heiberger H.B., Weinert L., Decara J., Lang R.M., Hibbard J.U. Prognostic value of echocardiography in peripartum cardiomyopathy Obstet Gynecol 2005 ;  105 : 1303-1308 [cross-ref]
Cooper L.T., Mather P.J., Alexis J.D., and al. Myocardial recovery in peripartum cardiomyopathy: prospective comparison with recent onset cardiomyopathy in men and nonperipartum women J Card Fail 2012 ;  18 : 28-33 [cross-ref]
Elkayam U., Tummala P.P., Rao K., and al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy N Engl J Med 2001 ;  344 : 1567-1571 [cross-ref]
Elkayam U., Akhter M.W., Singh H., and al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation Circulation 2005 ;  111 : 2050-2055 [cross-ref]
Felker G.M., Jaeger C.J., Klodas E., and al. Myocarditis and long-term survival in peripartum cardiomyopathy Am Heart J 2000 ;  140 : 785-791 [inter-ref]
Fett J.D., Christie L.G., Carraway R.D., Murphy J.G. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution Mayo Clin Proc 2005 ;  80 : 1602-1606 [cross-ref]
Forster O., Hilfiker-Kleiner D., Ansari A.A., and al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy Eur J Heart Fail 2008 ;  10 : 861-868 [cross-ref]
Gunderson E.P., Croen L.A., Chiang V., Yoshida C.K., Walton D., Go A.S. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes Obstet Gynecol 2011 ;  118 : 583-591 [cross-ref]
Habli M., O’Brien T., Nowack E., Khoury S., Barton J.R., Sibai B. Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome Am J Obstet Gynecol 2008 ;  199 : [415e1–415e5].
Haghikia A., Podewski E., Libhaber E., and al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy Basic Res Cardiol 2013 ;  108 : 366
Harper M.A., Meyer R.E., Berg C.J. Peripartum cardiomyopathy: population-based birth prevalence and 7-year mortality Obstet Gynecol 2012 ;  120 : 1013-1019
Hasan J.A., Qureshi A., Ramejo B.B., Kamran A. Peripartum cardiomyopathy characteristics and outcome in a tertiary care hospital J Pak Med Assoc 2010 ;  60 : 377-380
Huang G.Y., Zhang L.Y., Long-Le M.A., Wang L.X. Clinical characteristics and risk factors for peripartum cardiomyopathy Afr Health Sci 2012 ;  12 : 26-31
Isezuo S.A., Abubakar S.A. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital Ethn Dis 2007 ;  17 : 228-233
Kamiya C.A., Kitakaze M., Ishibashi-Ueda H., and al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. Results from the Japanese nationwide survey of peripartum cardiomyopathy Circ J 2011 ;  75 : 1975-1981 [cross-ref]
Kao D.P., Hsich E., Lindenfeld J. Characteristics, adverse events, and racial differences among delivering mothers with peripartum cardiomyopathy JACC Heart Fail 2013 ;  1 : 409-416 [cross-ref]
Karaye K.M., Yahaya I.A., Lindmark K., Henein M.Y. Serum selenium and ceruloplasmin in nigerians with peripartum cardiomyopathy Int J Mol Sci 2015 ;  16 : 7644-7654 [cross-ref]
Karaye K.M., Lindmark K., Henein M. Right ventricular systolic dysfunction and remodelling in Nigerians with peripartum cardiomyopathy: a longitudinal study BMC Cardiovasc Disord 2016 ;  16 : 27
Li W., Li H., Long Y. Clinical characteristics and long-term predictors of persistent left ventricular systolic dysfunction in peripartum cardiomyopathy Can J Cardiol 2016 ;  32 : 362-368 [cross-ref]
Libhaber E., Sliwa K., Bachelier K., Lamont K., Bohm M. Low systolic blood pressure and high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathy Int J Cardiol 2015 ;  190 : 376-382 [cross-ref]
Liu J., Wang Y., Chen M., and al. The correlation between peripartum cardiomyopathy and autoantibodies against cardiovascular receptors PLoS One 2014 ;  9 : e86770
Loyaga-Rendon R.Y., Pamboukian S.V., Tallaj J.A., and al. Outcomes of patients with peripartum cardiomyopathy who received mechanical circulatory support. Data from the Interagency Registry for Mechanically Assisted Circulatory Support Circ Heart Fail 2014 ;  7 : 300-309 [cross-ref]
Mandal D., Mandal S., Mukherjee D., and al. Pregnancy and subsequent pregnancy outcomes in peripartum cardiomyopathy J Obstet Gynaecol Res 2011 ;  37 : 222-227 [cross-ref]
Mishra T.K., Swain S., Routray S.N. Peripartum cardiomyopathy Int J Gynaecol Obstet 2006 ;  95 : 104-109 [cross-ref]
Modi K.A., Illum S., Jariatul K., Caldito G., Reddy P.C. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States Am J Obstet Gynecol 2009 ;  201 : [171e1–171e5].
Ntusi N.B., Badri M., Gumedze F., Sliwa K., Mayosi B.M. Pregnancy-associated heart failure: a comparison of clinical presentation and outcome between hypertensive heart failure of pregnancy and idiopathic peripartum cardiomyopathy PLoS One 2015 ;  10 : e0133466
Peradejordi M., Favaloro L.E., Bertolotti A. Predictors of mortality or heart transplantation in peripartum cardiomyopathy Argentine J Cardiol 2013 ;  81 : 41-48
Pillarisetti J., Kondur A., Alani A., and al. Peripartum cardiomyopathy: predictors of recovery and current state of implantable cardioverter-defibrillator use J Am Coll Cardiol 2014 ;  63 : 2831-2839 [cross-ref]
Saltzberg M.T., Szymkiewicz S., Bianco N.R. Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator J Card Fail 2012 ;  18 : 21-27 [cross-ref]
Sarojini A., Sai Ravi Shanker A., Anitha M. Inflammatory markers: serum level of C-Reactive Protein, tumor necrotic factor-alpha, and interleukin-6 as predictors of outcome for peripartum cardiomyopathy J Obstet Gynaecol India 2013 ;  63 : 234-239 [cross-ref]
Shah I., Zeb S., Hafizullah M., Shah S.T., Faheem M., Ullah R. Peripartum cardiomyopathy: risk factors, hospital course and prognosis; experiences at Lady Reading Hospital Peshawar Pak Heart J 2012 ;  45 : 108-115
Shani H., Kuperstein R., Berlin A., Arad M., Goldenberg I., Simchen M.J. Peripartum cardiomyopathy – risk factors, characteristics and long-term follow-up J Perinat Med 2015 ;  43 : 95-101
Sharieff S., Shah e Zaman K. Identification of Risk factors and demographic features of patients with peripartum cardiomyopathy J Coll Physicians SurgPak 2002 ;  12 : 410-414
Sliwa K., Skudicky D., Candy G., Bergemann A., Hopley M., Sareli P. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy Eur J Heart Fail 2002 ;  4 : 305-309 [cross-ref]
Sliwa K., Forster O., Libhaber E., and al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients Eur Heart J 2006 ;  27 : 441-446 [cross-ref]
Sliwa K., Blauwet L., Tibazarwa K., and al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study Circulation 2010 ;  121 : 1465-1473 [cross-ref]
Tibazarwa K., Lee G., Mayosi B., Carrington M., Stewart S., Sliwa K. The 12-lead ECG in peripartum cardiomyopathy Cardiovasc J Afr 2012 ;  23 : 322-329 [cross-ref]
Miller M.A., Ulisney K., Baldwin J.T. INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support): a new paradigm for translating registry data into clinical practice J Am Coll Cardiol 2010 ;  56 : 738-740 [cross-ref]
The Interagency Registry for Mechanically Assisted Circulatory Support  :  (2016). 



© 2018  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline